Compare Sana Biotechnology Inc (SANA) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs TJX Companies Inc — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $1.03B), while TJX Companies Inc trades at $126.94 (market cap $141.81B). The key difference: TJX Companies Inc is far larger — about 137.7× Sana Biotechnology Inc's market cap, and TJX Companies Inc pays a 1.49% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | TJX | |
|---|---|---|
Market Cap | $1.03B | $141.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $168.41 |
52-Week Low | $2.68 | $126.10 |
Enterprise Value | $946.04M | $150.12B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
TJX Companies trades at $128.91, down 2.4% on the day, with technical indicators showing bearish momentum despite strong fundamentals. The company reported consistent earnings beats in recent quarters with Q2 2026 EPS of $1.22 exceeding the $1.19 estimate. Revenue growth remains robust, climbing from $48.5B in 2022 to $56.4B in 2025, while net margins improved to 8.63%. Recent news highlights TJX's expansion plans, raising its global store target to 7,500 locations.
The investment outlook remains positive given strong analyst support (84.6% buy ratings) and a $169 consensus price target representing 31% upside. However, near-term technical weakness and valuation concerns present risks. The stock's current P/E of 23.87 appears reasonable given the company's 62% ROE and consistent execution, though competitive pressures in off-price retail warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
